Lilly says gene editing therapy cut bad cholesterol in early-stage trial

Eli Lilly (LLY) announced that its gene editing candidate VERVE-102, added from its $1.3B acquisition of Verve Therapeutics last year, caused up to a 62% average decline in low-density lipoprotein ...

‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose

One and done? Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up ...

Heart disease breakthrough: Eli Lilly’s one-shot gene therapy shows promise in cutting ‘bad’ cholesterol

Eli Lilly said its experimental gene-editing therapy cut LDL, or “bad,” cholesterol by up to 62% in an early-stage trial, ...
CNBCTV18

Eli Lilly-backed gene-editing therapy cuts ‘bad’ cholesterol by up to 62% in early trial

In an early-stage trial involving 35 high-risk patients, LDL or bad cholesterol fell by up to 62% after a single infusion of ...
Hosted on MSN

Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to face off with Ozempic maker Novo Nordisk. Eli Lilly said in a news release ...